Article Text
Abstract
This paper argues that the National Institute for Health and Clinical Excellence should not offer guidance in situations where there is insufficient evidence equipoise about the potential benefit of the treatment in question. This is broadly for two reasons. First, without knowing if the treatment is effective no cost-effectiveness judgement can be logically made. Second, the implementation of a population wide change in treatment where there is equipoise amounts to a de facto clinical trial that falls outside the Clinical Trials Regulations. As such there are strong ethical and possibly legal grounds for preventing such an outcome.
Guidance based upon insufficient evidence equipoise also impacts upon the clinical discretion possessed by individual medical professionals.
- NICE
- equipoise
- ethics
- allocation of healthcare resources
- population policy
- policy guidelines/inst. review boards/review Cttes
Statistics from Altmetric.com
Footnotes
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Other content recommended for you
- Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis
- NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
- Risk and outcomes of aortic valve endocarditis among patients with bicuspid and tricuspid aortic valves
- Prophylactic antibiotic use for infective endocarditis: a systematic review and meta-analysis
- Do patients at risk of infective endocarditis need antibiotics before dental procedures?
- Temporal association between invasive procedures and infective endocarditis
- Infective endocarditis at a tertiary care hospital in South Korea
- Commentary on endocarditis prophylaxis: a quaint custom or medical necessity?
- Vitamin K deficiency bleeding after NICE guidance and withdrawal of Konakion Neonatal: British Paediatric Surveillance Unit study, 2006–2008
- Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study